A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients

Background: Abiraterone acetate was approved by FDA and EMA in April and September 2011, respectively for treatment of patients with casteration resistant prostate cancer and those previously treated with docetaxel. It is a selective inhibitor of androgen biosynthesis which potentially and irreversi...

Descripción completa

Detalles Bibliográficos
Autores principales: James, Aloysius, Vincent, Bini, Sivadas, Akhila, Pavithran, K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018245/
https://www.ncbi.nlm.nih.gov/pubmed/29951171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018245/
https://www.ncbi.nlm.nih.gov/pubmed/29951171

Ejemplares similares